Drug Profile
Zanidatamab zovodotin - Zymeworks
Alternative Names: anti-HER2 x HER2 ADC - Zymeworks; ZW-49Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I HER2 positive breast cancer; Oesophageal cancer; Solid tumours
- Preclinical Gastric cancer
Most Recent Events
- 04 Jan 2024 Zymeworks plans a phase II trial for zanidatamab zovodotin in non-small cell lung cancer in 2024
- 11 Oct 2023 Efficacy, adverse event, and pharmacokinetics data from a phase I trial in Oesophageal-cancer, Solid-tumours , and HER2-positive-breast-cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 28 Apr 2023 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV)